Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: nitric oxide-donors - NicOx/Re-Vana Therapeutics

Next Previous
Drug Profile

Research programme: nitric oxide-donors - NicOx/Re-Vana Therapeutics

Alternative Names: NCX-1660; NCX-667; Research programme: eye disorders therapeutics - NicOx/Re-Vana Therapeutics

Latest Information Update: 02 Jan 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NicOx
  • Developer NicOx; Re-Vana Therapeutics
  • Class Antiglaucomas; Eye disorder therapies; Nitroso compounds
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glaucoma; Ocular hypertension

Most Recent Events

  • 21 Dec 2018 Discontinued for Glaucoma in France (Ophthalmic)
  • 21 Dec 2018 Discontinued for Ocular hypertension in France (Ophthalmic)
  • 20 Oct 2017 Nicox and Re-Vana Therapeutics enter into a collaboration agreement to develop sustained release formulations of nitric oxide donating compounds for Glaucoma and Ocular hypertension

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top